8Katano M,Morisaki T.The past,the present and future of the OK-432 therapy for patients with malignant effusions[J].Anticancer Res,1998,18(5D):3917-3925.
9Cardillo G,Facciolo F,Carbone L,et al.Long-term follow up of video-assisted talc pleurodesis in malignant recurrent pleural effusions[J].Eur J Cardiothorac Surg,2002,21(2):302-305.
10Genc O,Petrou M,Ladas G,et al.The long-term morbidity of Pleuroperitoneal shunts in the management of recurrent malli gnant effusions[J].Eur J Cardiothorac Surg,2000,18(2):143-146.
5Fidler IJ. The pathogenesis of cancer metastasis: the ' seed and soil' hypothesis revisited. Nature Rev Cancer,2003,3 (6) :453-458.
6Dejmek A,Yahata N,Ohynshiki K,et al.Correlation between morphology and telomerase activity in cells from exfoliatire lung egtologlc specimens[J].Cancer,2000,90(2):117-125.
7Albanell J,Lonardo F,Rusch Y,et al.High telomerase activity in primary lung cancer:association with increased cell proliferation rates and advanced pathologic stage[J].J Natl Cancer Inst,1997,89(21):1609-1615.
8Perry PJ,Jenkins TC.Recent advances in the development of telomerase inhibitors for the treatment of cancer[J].Expert Opin Investig Drugs,1999,8(12):1981-2008.
